345 related articles for article (PubMed ID: 30275091)
1. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
Wu X; Venkataramanan R; Rivosecchi RM; Tang C; Marini RV; Shields RK; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767725
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
[TBL] [Abstract][Full Text] [Related]
4. A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.
Decembrino N; Perruccio K; Zecca M; Colombini A; Calore E; Muggeo P; Soncini E; Comelli A; Molinaro M; Goffredo BM; De Gregori S; Giardini I; Scudeller L; Cesaro S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871077
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation.
Kabulski GM; MacVane SH
Transpl Infect Dis; 2018 Jun; 20(3):e12878. PubMed ID: 29512930
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
[TBL] [Abstract][Full Text] [Related]
9. [Invasive aspergillosis in solid organ transplantation].
Silva JT; Torre-Cisneros J; Aguado JM
Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
[TBL] [Abstract][Full Text] [Related]
10. Preexposure to Isavuconazole Increases the Virulence of
Wurster S; Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455245
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients.
Silva JT; Husain S; Aguado JM
Transpl Int; 2023; 36():11845. PubMed ID: 38161768
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
Monforte A; Los-Arcos I; Martín-Gómez MT; Campany-Herrero D; Sacanell J; Berastegui C; Márquez-Algaba E; Sempere A; Nuvials X; Deu M; Castells L; Moreso F; Bravo C; Gavaldà J; Len O
Microbiol Spectr; 2022 Feb; 10(1):e0178421. PubMed ID: 35171022
[TBL] [Abstract][Full Text] [Related]
14. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
15. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Rybak JM; Marx KR; Nishimoto AT; Rogers PD
Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
Lepak AJ; Marchillo K; VanHecker J; Diekema D; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5642-8. PubMed ID: 24002092
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
[TBL] [Abstract][Full Text] [Related]
18. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
Seyedmousavi S; Verweij PE; Mouton JW
Expert Rev Anti Infect Ther; 2015 Jan; 13(1):9-27. PubMed ID: 25488140
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
